<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38279427</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1165-158X</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>15</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Cellular and molecular biology (Noisy-le-Grand, France)</Title><ISOAbbreviation>Cell Mol Biol (Noisy-le-grand)</ISOAbbreviation></Journal><ArticleTitle>Anti- IL-22 neutralizing antibodies decrease inflammation lesions and reduce mortality in enterovirus 71-infected mice.</ArticleTitle><Pagination><StartPage>254</StartPage><EndPage>258</EndPage><MedlinePgn>254-258</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14715/cmb/2023.69.15.42</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) can cause fatal encephalitis in 0-5-year-old infants and children. There is no effective antiviral drug available to treat HFMD caused by enterovirus 71 (EV71). Our study investigates the relationship between levels of IL-22 expression and the severity of disease after EV71 infection in a mouse model. Anti-IL-22 neutralizing antibodies were tested in EV71-infected mice of different ages. Our results show that anti-IL-22 neutralizing antibodies can effectively reduce mortality in EV71-infected mice. Anti-IL-22 neutralizing antibody effectively reduced various EV71-associated symptoms indicating promising potential of this therapeutic effector in patients with EV71-associated HFMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, Peking University Shougang Hospital, Beijing, China. Chang_z@yeah.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Sa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, Peking University Shougang Hospital, Beijing, China. 672506803@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, Peking University Shougang Hospital, Beijing, China. Zongxue123zx@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Lian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Peking University Shougang Hospital, Beijing, China. 06040409@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yunfan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Peking University Shougang Hospital, Beijing, China. Wangtaozyy@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Cell Mol Biol (Noisy-le-grand)</MedlineTA><NlmUniqueID>9216789</NlmUniqueID><ISSNLinking>0145-5680</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097043">Interleukin-22</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097043" MajorTopicYN="N">Interleukin-22</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>27</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38279427</ArticleId><ArticleId IdType="doi">10.14715/cmb/2023.69.15.42</ArticleId></ArticleIdList></PubmedData></PubmedArticle>